FindTrial
Sign In

TAB004

DRUG2 trials

Sponsors

Shanghai Junshi Biosciences Co. Ltd., TopAlliance Biosciences

Conditions

Advanced Unresectable Solid TumorMetastatic Solid TumorPatients with limited-stage small cell lung cancer (LS-SCLC) without disease progression after chemoradiotherapy (CRT)

Phase 1

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
RecruitingNCT04137900
TopAlliance BiosciencesAdvanced Unresectable Solid Tumor, Metastatic Solid Tumor
Start: 2019-10-30End: 2026-03-31Target: 499Updated: 2024-02-05

Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
RecruitingCTIS2023-507097-41-01
Shanghai Junshi Biosciences Co. Ltd.Patients with limited-stage small cell lung cancer (LS-SCLC) without disease progression after chemoradiotherapy (CRT)
Start: 2025-03-20Target: 149Updated: 2025-11-19

Related Papers

Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients
OncoImmunology2024-06-264 citations
Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies.
Journal of Clinical Oncology2024-06-014 citations
Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.
Journal of Clinical Oncology2022-06-0118 citations